公开(公告)号：EP3978073A1

公开(公告)日：2022-04-06

申请号：EP20815167.0

申请日：2020-05-29

申请人： Ube Industries, Ltd.

发明人： KOMORI, Ken-ichi ,  NISHIYAMA, Hayato ,  KINOSHITA, Naoya ,  WADA, Yukinori ,  MORISHITA, Kousuke ,  NINOMIYA, Akishi ,  SHIRAISHI, Yuusuke ,  ONUMA, Kazuhiro ,  OGI, Sayaka ,  KAWADA, Hiroyoshi ,  KIMURA, Tomio

IPC分类号： A61P13/12 ,  A61P43/00 ,  C07D413/10 ,  C07D498/04 ,  A61K31/553

摘要： The present invention provides a compound having Keap1 inhibitory effects and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following general formula (I):

[wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

公开(公告)号：EP3214086A1

公开(公告)日：2017-09-06

申请号：EP15855181.2

申请日：2015-10-30

申请人： Ube Industries, Ltd.

发明人： AGA, Yasuhiro ,  USHIYAMA, Shigeru ,  IWASE, Noriaki ,  KONO, Shigeyuki ,  SUNAMOTO, Hidetoshi ,  MATSUSHITA, Takashi ,  OGI, Sayaka ,  TANAKA, Masayuki ,  MATOYAMA, Masaaki ,  UMEZAKI, Satoshi ,  SHIRAISHI, Yusuke ,  ONUMA, Kazuhiro ,  KOJIMA, Masahiro ,  NISHIYAMA, Hayato ,  KIMURA, Tomio

IPC分类号： C07F7/10 ,  A61K31/695 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P43/00

CPC分类号： C07F7/10 ,  A61K31/695 ,  Y02P20/55

摘要： Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof:

wherein L 1 is an optionally substituted C 1-6 alkylene group or the like, L 2 is a single bond or the like, L 3 is a single bond or the like, R 1 , R 2 , and R 3 are each independently an optionally substituted C 1-4 alkyl group or the like, R 4 is a hydrogen atom or the like, and R 5 is a hydrogen atom or the like.

摘要翻译： 提供由式（I）表示的化合物或其药理学上可接受的盐：其中L 1是任选取代的C 1-6亚烷基等，L 2是单键等，L 3是单键等， R1，R2和R3各自独立地为任选取代的C1-4烷基等，R4为氢原子等，R5为氢原子等。